Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 3, 2010, Pages 147-153

  Dworzak, Michael N ^a   Gaipa, Giuseppe ^b   Schumich, Angela ^a   Maglia, Oscar ^b   Ratei, Richard ^c   Veltroni, Marinella ^d,e   Husak, Zvenyslava ^a   Basso, Giuseppe ^d   Karawajew, Leonid ^c   Gadner, Helmut ^a   Biondi, Andrea ^b  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b SAN GERARDO HOSPITAL   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antigen expression; Flow cytometry; Lymphoblastic leukemia; Minimal residual disease; Phenotype

Indexed keywords

ASPARAGINASE; CD20 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPHENOTYPING; LEUKEMIA CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; INFANT; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77952630014     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20516     Document Type: Article

References (22)

1. Lavabre-Bertrand T, Janossy G, Ivory K, Peters R, Secker-Walker L, Porwit-Macdonald A. Leukemia-associated changes identified by quantitative flow cytometry. I. CD10 expression. Cytometry 1994; 18:209-217.
2. Dworzak MN, Fritsch G, Fleischer C, Printz D, Fröschl G, Buchinger P, Mann G, Gadner H. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol 1998;26:305-313. (Pubitemid 28177788)
3. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-152. (Pubitemid 29390417)
4. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-Macdonald A, Faria T, Bjorklund E, Biondi A, van den Beemd MW, Baars E, Vidriales B, Parreira A, van Dongen JJ, San Miguel JF, Orfao A. BIOMED-1 concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standard triple-stainings. Leukemia 2001;15:1185-1192.
5. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group. Cytometry B (Clin Cytom) 2005;68B:18-24. (Pubitemid 41566359)
6. Dworzak MN, Fröschl G, Printz D, de Zen L, Gaipa G, Ratei R, Basso G, Biondi A, Ludwig WD, Gadner H. CD99 expression in T-lineage ALL: Implications for flow cytometric detection of minimal residual disease. Leukemia 2004;18:703-708. (Pubitemid 38500188)
7. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak MN; for the I-BFM-ALL-FCM-MRD Study Group. Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection. Leukemia 2005;19:49-56.
8. Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM. Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: Selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003;17:2130-2139. (Pubitemid 37428378)
9. Diaz D, Prieto A, Barcenilla H, Monserrat J, Prieto P, Sanchez MA, Reyes E, Hernandez-Fuentes MP, de la Hera A, Orfao A, Alvarez-Mon M. Loss of lineage antigens is a common feature of apoptotic lymphocytes. J Leukoc Biol 2004;76:609-615. (Pubitemid 39129093)
10. van der Sluijs-Gelling AJ, van der Velden VHJ, Roeffen ETJM, Veerman AJP, van Wering ER. Immunophenotypic modulation in childhood precursor B-ALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 2005;19:1845-1847.
11. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, Faini A, Veltroni M, Husak D, Schumich A, Ratei R, Biondi A, Dworzak MN; on behalf of the I-BFM-ALL-FCM-MRD Study Group. Prednisone induces immunophenotypic modulation of CD10 and CD34 in non-apoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B (Clin Cytom) 2008;74B:150-155.
12. Kumagai M, Manabe A, Coustan-Smith E, Blakley RL, Beck WT, Santana VM, Behm FG, Raimondi SC, Campana D. Use of stromasupported cultures of leukemic cells to assess antileukemic drugs. II. Cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia 1994;8:1116-1123.
13. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992;79:2370-2377.
14. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, Karawajew L, Benetello A, Pötschger U, Husak Z, Gadner H, Biondi A, Ludwig W-D, Basso G. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multi-centric assessment is feasible. Results of the AIEOP-BFM-ALLFCM-MRD Study Group. Cytometry B (Clin Cytom) 2008;74B:331-340.
15. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, Fritsch G, Gadner H; for the Austrian Berlin-Frankfurt- Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952-1958.
16. Veltroni O, de Zen O, Sanzari MC, Maglia O, Dworzak MN, Ratei R, Biondi A, Basso G, Gaipa G; on behalf of the I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003;11:1245-1252.
17. Lenkei R, Gratama JW, Rothe G, Schmitz G, D'hautcourt JL, Arekrans A. Performance of calibration standards for antigen quantification with flow cytometry. Cytometry 1998;33:188-196.
18. Gaipa G, Basso G, Ratei R, Biondi A, Dworzak M. Reply to van der-Sluijs-Gelling et al. Leukemia 2005;19:2351-2352.
19. Rhein P, Scheid S, Ratei R, Hagemeier C, Seeger K, Kirschner-Schwabe R, Moericke A, Schrappe M, Spang R, Ludwig W-D, Karawajew L. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterise leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2007;21:897-905.
20. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmüller C, Presul E, Skvortsov S, Crazzolara R, Fiegl M, Raivio T, Jänne OA, Geley S, Meister B, Kofler R. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006; 107:2061-2069. (Pubitemid 43292367)
21. Dworzak MN, Fritsch G, Fleischer C, Printz D, Fröschl G, Buchinger P, Mann G, Gadner H. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia 1997;11:1266-1273. (Pubitemid 27387303)
22. Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, Basso G, Gaipa G, Ratei R, Mann G, Gadner H. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: Setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982-3988.